Unknown PHASE1 INTERVENTIONAL 3-arm NCT00520104

Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine

A Randomized, Open Label, Single Center, Single-Dose Study to Assess the Effects of Certain Nasal Medications on the Pharmacokinetics, Safety and Tolerability of PMI-150 (Intranasal Ketamine Hydrochloride) 30 mg

Sponsor: Javelin Pharmaceuticals

Conditions Pharmacokinetics

Interventions intranasal ketamine

Updated 6 times since 2017 Last updated: Feb 27, 2008 Started: Aug 31, 2007 Primary completion: Feb 29, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pharmacokinetics and is currently ongoing. Javelin Pharmaceuticals leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Javelin Pharmaceuticals

Data source: Javelin Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United States